mynth
11/2021MajoritySecondary Buyout

Essling Capital / Multicroissance / Bourrelier Group take majority stake in Teknimed

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics REV €5–25M

Context

Essling Capital took a majority stake in Teknimed in November 2021, through its Essling Expansion fund, buying from Apax Development, Crédit Mutuel Equity and Bpifrance, which had held the company since 2015. It acquired the majority alone, with Multicroissance and Bourrelier Group, the investment vehicle of Bricorama founder Jean-Claude Bourrelier, joining as co-investors. The transaction took the form of a pre-emptive offer prepared from the start of the year, which forestalled the auction expected for the end of it. Founded in Toulouse, Teknimed develops and manufactures implantable biomaterials, principally bone cements for spinal and orthopaedic surgery. These are the compounds surgeons use to anchor a prosthesis to the bone or to fill and stabilise a vertebra, setting in place during the operation itself, which makes their handling properties as critical as their composition. The company generated revenue of €5–25M, more than 80% of it outside France, across other European countries, Asia, South America and North America. It does not sell to hospitals directly, but through distributors of orthopaedic equipment, and supplies larger device manufacturers that resell its cements within kits alongside their own products. Extending that second channel was central to its plan: producing biomaterials under white label, to its customers’ own specifications, for the major manufacturers in the field. The production site had been extended with new cleanrooms in 2018, giving it capacity for three times its output. The investors backed an acceleration in North America and acquisitions to widen the product range. Alvarez & Marsal, Avicenne Développement and Goodwill Partners carried out financial, strategic and environmental due diligence for the investors, with Dentons as legal counsel. Potomac Transactions and Villechenon advised the sellers, while LBO Managers, Finadoc and Volt Associés acted for the company and De Pardieu Brocas Maffei for the senior lenders.

-> Deep-dive in Healthcare & Pharma market trends

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2020
€5–25M
€0–5M
€0–5M
2019
€5–25M
€0–5M
€0–5M

Other operations with Teknimed

Other operations with Teknimed
DateAcquirerTargetCountrySector
07/2026APHEONTEKNIMEDFRANCEImplants & Prosthetics
06/2015APAX PARTNERS / CREDIT MUTUEL EQUITY / BPIFRANCETEKNIMEDFRANCEImplants & Prosthetics

Other operations with Essling Capital / Multicroissance / Bourrelier Group

Other operations with Essling Capital / Multicroissance / Bourrelier Group
DateAcquirerTargetCountrySector
12/2023ESSLING CAPITALX-RAY PHOCEAFRANCERadiology

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
12/2021PLANMECA GROUPKAVO DENTALGERMANYMedical Devices
12/2021INTEGEROSCORUNITED STATESImplants & Prosthetics
11/2021COLOPLASTATOS MEDICALSWEDENMedical Consumables
09/2021PERRIGO COMPANYHRA PHARMAFRANCEGenerics / Labs
07/2021ORKLANUTRAQNORWAYNutrition & Dietary Supplements
07/2021PARTNERS GROUPPHARMATHENGREECECDMO
07/2021MONTAGU PRIVATE EQUITYINTECH MEDICALFRANCEImplants & Prosthetics
04/2021NAXICAP PARTNERSLAGARRIGUEFRANCEImplants & Prosthetics
04/2021NESTLETHE BOUNTIFUL COMPANYUNITED STATESNutrition & Dietary Supplements
04/2021DIASORINLUMINEX CORPORATIONUNITED STATESDiagnostic Equipment

REFERENCES

Revenue range: REV €5–25M

EBITDA range: €0–5M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Teknimed by Essling Capital / Multicroissance / Bourrelier Group are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: teknimed

Acquirer: bourrelier group / essling capital / multicroissance

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Teknimed, a French company specialised in Medical Devices, by Essling Capital, Multicroissance and Bourrelier Group in 2021, through a secondary sponsor-to-sponsor buyout. This followed a prior holding cycle initiated by Apax Partners / Credit Mutuel Equity / Bpifrance in June 2015, before ownership was subsequently transferred to Apheon in July 2026 (see dedicated deal pages for details).

What were Teknimed’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Teknimed generated annual revenue estimated in the €5–25M range and EBITDA in the €0–5M bracket (FY 2020). Detailed financial figures are available to members.

How does the valuation of Teknimed compare to benchmarks in the Healthcare & Pharma sector?

Transaction multiples for this specific deal are exclusively reserved for mynth members. Nevertheless, transactions tracked by mynth in this sector reveal an average benchmark multiple of 14.8x EBITDA during 2021.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.